Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05729594 · ClinicalTrials.gov registry record · Phase 1
Systemic Pharmacokinetic Study of T4032 (Unpreserved Bimatoprost 0.01%) Eye Gel Versus Lumigan® 0.01% Eye Drops in 40 Healthy Volunteers
A Phase 1 study, sponsored by Laboratoires Thea.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT05729594 is a Phase 1 study that has completed, run by Laboratoires Thea. The registered enrollment target is 40 participants.
The verdict
NCT05729594, a Phase 1 study, has completed, sponsored by Laboratoires Thea.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
This study is being performed to compare the systemic pharmacokinetic profiles of T4032 and Lumigan 0.01% given that T4032 has a different formulation (in terms of excipients) from the reference product.
Interventions
- DRUG Bimatoprost Ophthalmic
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2023-02-27 |
| Est. Completion | 2023-04-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05729594
The ClinicalTrials.gov registry entry for NCT05729594 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Laboratoires Thea, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Bimatoprost Ophthalmic is the first listed.
NCT05729594 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05729594 about?
NCT05729594 is a clinical study titled "Systemic Pharmacokinetic Study of T4032 (Unpreserved Bimatoprost 0.01%) Eye Gel Versus Lumigan® 0.01% Eye Drops in 40 Healthy Volunteers". This study is being performed to compare the systemic pharmacokinetic profiles of T4032 and Lumigan 0.01% given that T4032 has a different formulation (in terms of excipients) from the reference product.
What is the current status of trial NCT05729594?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2023-02-27. Estimated completion is 2023-04-05.
What interventions are being tested in trial NCT05729594?
The interventions under investigation include: Bimatoprost Ophthalmic (DRUG).
Who is sponsoring clinical trial NCT05729594?
This trial is sponsored by Laboratoires Thea, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.